HEPARIN SODIUM IN 5% DEXTROSE INJECTION, 25000UNIT/500ML 5 G / 100 ML
DEXTROSE : 5 G / 100 ML CITRIC ACID : 93 MG / 100 ML HEPARIN SODIUM : 5000 UNIT / 100 ML SODIUM PHOSPHATE DIBASIC : 410 MG / 100 ML · DIN 01935941 · B. BRAUN MEDICAL INC
Health Canada status: MARKETED
What is HEPARIN SODIUM IN 5% DEXTROSE INJECTION, 25000UNIT/500ML?
HEPARIN SODIUM IN 5% DEXTROSE INJECTION, 25000UNIT/500ML 5 G / 100 ML contains DEXTROSE : 5 G / 100 ML CITRIC ACID : 93 MG / 100 ML HEPARIN SODIUM : 5000 UNIT / 100 ML SODIUM PHOSPHATE DIBASIC : 410 MG / 100 ML. It is listed in the Health Canada Drug Product Database under DIN 01935941, held by B. BRAUN MEDICAL INC, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 03-Sep-1998. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is HEPARIN SODIUM IN 5% DEXTROSE INJECTION, 25000UNIT/500ML used for?
Anticoagulant therapy; prophylaxis/treatment of venous thrombosis, pulmonary embolism, peripheral arterial embolism; atrial fibrillation with embolization; DIC; prevention of clotting in surgery.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 01935941 |
|---|---|
| Brand name | HEPARIN SODIUM IN 5% DEXTROSE INJECTION, 25000UNIT/500ML |
| Generic / active ingredient | DEXTROSE : 5 G / 100 ML CITRIC ACID : 93 MG / 100 ML HEPARIN SODIUM : 5000 UNIT / 100 ML SODIUM PHOSPHATE DIBASIC : 410 MG / 100 ML |
| Manufacturer | B. BRAUN MEDICAL INC |
| Strength | 5 G / 100 ML |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Ethical |
| ATC code | B01AB51 HEPARIN, COMBINATIONS |
| AHFS class | 20:12.04.16 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 03-Sep-1998 |
| Original market date | 1993-12-31 00:00:00 |
How is it administered?
Continuous IV infusion following initial IV bolus. Adjust dose based on APTT (1.5-2x normal). Typical adult dose: 20,000-40,000 units/24 hours. Do not use as catheter lock flush.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at room temperature (25°C); brief exposure up to 40°C permitted. Protect from freezing. Avoid excessive heat.
How is it supplied?
Plastic containers (Excel Container). Available in 20,000 units and 25,000 units strengths.
Contraindications
Severe thrombocytopenia; inability to perform coagulation tests; uncontrollable active bleeding (except DIC); hypersensitivity to heparin, corn products, or sulfites.
Warnings and precautions
Serious Warning: Fatal medication errors in pediatrics (confusion with lock flush). Risk of hemorrhage at any site. Heparin-induced thrombocytopenia (HIT/HITT). Contains sodium metabisulfite.
What can be used instead?
Other Canadian products sharing ATC code B01AB51 HEPARIN, COMBINATIONS. 4 of 8 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| HEPARIN SOD AND 0.9% SOD CHLORIDE INJ | 2 UNIT | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 00828750 |
| HEPARIN SODIUM 20000UNITS IN 5% DEXTROSE INJ | 4000 UNIT / 100 ML | SOLUTION | B. BRAUN MEDICAL INC | MARKETED | DIN 02209713 |
| HEPARIN SODIUM 25000UNITS IN 5% DEXTROSE INJ | 5 G / 100 ML | SOLUTION | B. BRAUN MEDICAL INC | MARKETED | DIN 02209721 |
| HEPARIN SODIUM & 5% DEXTROSE INJECTION LIQ | 5 G / 100 ML | SOLUTION | BAXTER CORPORATION | CANCELLED POST MARKET | DIN 02008181 |
| HEPARIN SODIUM & DEXTROSE 5% IN VIAFLEX LIQ | 5 G / 100 ML | SOLUTION | BAXTER CORPORATION | CANCELLED POST MARKET | DIN 01900757 |
| HEPARIN SODIUM AND DEXTROSE 5% INJ USP | 5 G / 100 ML | LIQUID | BAXTER CORPORATION | CANCELLED POST MARKET | DIN 01913255 |
| HEPARIN SODIUM IN 0.9% SODIUM CHLORIDE INJECTION | 430 MG / 100 ML | SOLUTION | B. BRAUN MEDICAL INC | DORMANT | DIN 01935933 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Request a quote for HEPARIN SODIUM IN 5% DEXTROSE INJECTION, 25000UNIT/500ML
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.